Vertex Pharma reports RAINIER results as Vertex Pharma stock costs EUR 469.05
Published on 10/24/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKidney data and dates
- Vertex announced RAINIER results on October 23, 2026, including a 52.00 percent reduction in proteinuria at Week 36.
- Vertex Pharma stock costs EUR 469.05 at 10:21 a.m. CEST at Lang & Schwarz on October 24, 2026.
- The next Xetra session is scheduled for October 26, 2026.
Vertex Pharma reported Phase 3 RAINIER results for povetacicept in IgA nephropathy on October 23, 2026, while Vertex Pharma stock costs EUR 469.05 in weekend trading at Lang & Schwarz at 10:21 a.m. CEST on October 24, 2026. The company’s announcement was published by AFP.
Market context: Market report S&P 500.
The week in figures
The weekend-trading price from Lang & Schwarz was EUR 469.05 at 10:21 a.m. CEST on October 24, 2026. Xetra and the primary exchanges are closed during the weekend trading session.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
Chronology of the week
On October 23, 2026, Vertex announced the publication of Phase 3 RAINIER results and their presentation at the American Society of Nephrology Kidney Week 2026. In the Week 36 interim analysis, povetacicept reduced proteinuria by 52.0 percent from baseline and by 49.8 percent versus placebo. The company said 42.2 percent of treated participants reached 24-hour UPCR below 0.5 grams per gram, compared with 6.2 percent on placebo, according to AFP.
Vertex said the RAINIER data support its Biologics License Application for povetacicept in IgA nephropathy. The U.S. Food and Drug Administration’s Prescription Drug User Fee Act target action date is November 30, 2026, the company said in the AFP-published release.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. The company’s cited regulatory date for povetacicept is November 30, 2026.
